AMY THOMAS: Open Payments
NPI 1477163087 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,013 in 113 payments from 23 companies in 2025. Trend: 2023 $2,192 · 2024 $2,173 · 2025 $2,013
Food & beverage: $2,013
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $341 |
| ABBVIE INC. | 13 | $299 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $199 |
| Teva Pharmaceuticals USA, Inc. | 5 | $169 |
| Otsuka America Pharmaceutical, Inc. | 10 | $154 |
| Novo Nordisk Inc | 7 | $148 |
| Alkermes, Inc. | 7 | $126 |
| Janssen Pharmaceuticals, Inc | 5 | $86 |
| AstraZeneca Pharmaceuticals LP | 2 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, AUSTEDO XR, REXULTI, ARISTADA, INVEGA SUSTENNA, FARXIGA.
Industry payments across OK — which companies pay providers there.
